Nicotinamide to Prevent Delirium

Delirium Confusional State Clinical Trial

Official title:

Nicotinamide, an Inhibitor of PARP-1, for Preventing Delirium in Older Adults

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04725253
• Other study ID #: FONDECYT 11190882
• Status: Not yet recruiting
• Phase: N/A
• Start date: January 21, 2021
• Est. completion date: April 30, 2022

Study information

• Verified date: January 2021
• Source: University of Chile
• Contact: Felipe Salech, MD PhD
• Phone: +56998739448
• Email: fhsalech[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Delirium is defined as an acute change in mental status characterized by fluctuating disturbances of consciousness, attention, cognition, and perception, usually secondary to acute injuries such as trauma or infections. Delirium is more frequent in older adults, and is associated with important poor clinical outcomes including increased mortality, functional deterioration, and higher expenditures for healthcare systems.

Although it is not the only one responsible, the inflammatory response plays a key role in the development of delirium. From the first descriptions of the condition 2500 years ago, it is known that patients who present with inflammatory injuries such as trauma (pe. hip fracture) or infections (sepsis), frequently develop delirium. Microglia, are an inflammatory cell with phagocytic capacity, that inhabit the nervous system and have a critical role in the regulation of the inflammatory response in the brain. It is known that microglia have receptors that respond to systemic inflammatory mediators by generating new inflammatory mediators that exert their effect on other glial cells and neurons in the central nervous system, affecting their function. Mouse models have shown that depleting the brain of microglia prevents cognitive decline after a traumatic bone injury, suggesting a role of these cells in the development of delirium.

Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme that participates in DNA repair, and in the regulation of the expression of inflammatory mediators by immune cell. In vitro experiments have shown that PARP-1 enhances the microglial response to inflammation, and data from mice exposed to the bacterial component "lipo-poly-saccharide (LPS)", a classical model of delirium, showed that pharmacological inhibition of PARP-1 prevents cognitive decline secondary to that injury. Interestingly, nicotinamide, a vitamin widely available in the market, with a well-known safety profile in humans, is a well-recognized inhibitor of PARP-1. The role of PARP-1 nor nicotinamide in delirium has never been explored.

Considering that, 1) there is evidence showing that PARP-1 may act as an enhancer of the inflammatory response of microglia and 2) the protective effect against cognitive impairment produced by pharmacological inhibition of PARP-1 in a mice model of delirium, we propose as hypothesis that PARP-1 participates in delirium pathogenesis by enhancing microglial activation in response to systemic inflammation. To address this hypothesis in patients, we propose to determine in a randomized clinical trial whether nicotinamide, a pharmacological inhibitor of PARP-1, is more effective than placebo for the prevention of delirium in older adults with requirement of oxygen (non-invasive) and suspected coronavirus disease (COVID-19) under study.

The results of this research will contribute significantly in the field of delirium, improving the knowledge of its physiopathology, as well with the development of of new alternatives for its prevention in clinical practice.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 146
• Est. completion date: April 30, 2022
• Est. primary completion date: April 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• Older than 65 years old.

• Newly admitted due to suspected coronavirus disease (COVID-19) under study.

• To have less than 24 hours from the hospitalization at the moment of randomization.

• Able to take medicine orally.

• Signed an informed consent.

Exclusion Criteria:

• An expected stay or life expectancy of less than 48 hours.

• Severe liver dysfunction or Lewy body disease.

• Syndromes associated with alcohol dependency and drug abuse.

• Psychotic or bipolar disorders receiving treatment with antipsychotics.

• Delirious at admission Patients.

• Documented viral infections.

Related Conditions & MeSH terms

• Confusion
• Delirium
• Delirium Confusional State

Intervention

Dietary Supplement:
• Nicotinamide
Nicotinamide, 1,5 gr per day for 7 days.

Other:
• Placebo tablets
Placebo tablets, 1 per day for 7 days.

Locations

Country	Name	City	State
Chile	Hospital Clínico Universidad de Chile	Santiago

Sponsors (2)

Lead Sponsor	Collaborator
University of Chile	Fondo Nacional de Desarrollo Científico y Tecnológico, FONDECYT (Chile).

Country where clinical trial is conducted

Chile, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of delirium during the 1 week after injury.	The Confusion Assessment Method (CAM) will be used to measure delirium. CAM will be assessed between 10 and 11 a.m., and between 8 and 9 p.m. in all patients (twice a day for 7 days).	7 days